Objective: To describe the current state of treatment for disorders of intermediate metabolism (primarily of amino acids, urea cycle and organic acids) and for diseases related to two subcellular organelles (lysosomes and peroxisomes).
Background
Treatment of genetic diseases is a field of medicine that has seen significant advances over recent decades. An understanding of the pathophysiology of the majority of these conditions has made it possible to define metabolic management protocols that are able to minimize or even avert the clinical manifestations of many inborn errors of metabolism (IEM).
This process began with disorders of intermediate metabolism, but over recent years spectacular progress has also been made with IEM that involve larger molecules and subcellular organelles, as is the case of lysosomal diseases. In these cases, advances in biotechnology have not only made it possible to interfere with the synthesis of these molecules, but also to produce in laboratories the actual enzymes that are deficient in order to administer them to patients. Furthermore, there are new strategies in permanent development, involving, for example, recovery of residual enzyme activity using chaperones, cell therapy and gene therapy and also combination treatments.
This article focuses on those themes that we expect to be of greatest interest to pediatricians: management of intermediate IEM that cause "acute intoxication" and in which appropriate treatment in good time can very often save a life and even avoid sequelae; and the state of the art in terms of the newest treatments for storage diseases, involving innovative treatments, the majority of which are already available, but whose high cost has restricted access, prompting intense discussion.
Treatment of intermediate IEM
The significant progress that has been made in understanding the biochemical and molecular bases of intermediate IEM has paved the way for an ever growing arsenal of therapeutic options for the management of these conditions. Although for some diseases treatment possibilities are still restricted, either because knowledge of the basic defect is still lacking or because it has not proved possible to intervene in its course, this has been the area of genetics that has most benefited from new biotechnology tools which, together with older, but effective, techniques of special diets and cofactor supplementation, have meant that nowadays many IEM are treatable conditions.
In parallel, the development of more sophisticated and sensitive diagnostic methods, very often incorporated into neonatal screening programs, has made earlier and more precise diagnoses possible, often before symptoms of the disease manifest. This is particularly important to remember, since very often the occurrence of neurological damage is related to the duration and period of exposure to toxic metabolites. Therefore, correct intervention immediately after diagnosis is, in many cases, a fundamental determinant of prognosis in these cases.
In this article we will review the current status of IEM treatment with the intention of providing pediatricians with a practical and up-to-date overview of the therapeutic management of these situations. All of these conditions exhibit a certain similarity in terms of clinical manifestations: they do not compromise embryonic or fetal growth, patients have an interval after birth of variable duration free from symptoms before the signs and symptoms of "intoxication" manifest, whether in an acute manner (vomiting, coma, liver failure, thromboembolic complications) or chronically (growth and development deficits, visual disorders, cardiomyopathy, psychiatric symptoms). Symptoms may be triggered by changes to the catabolic state (fever, viral infections or reduced food intake). Early recognition of this group of pathologies is of fundamental importance since, for the majority of them, there are treatment options, whether with supplementation of certain vitamins or dietary changes. In the majority of cases, if treatment is instituted early enough, clinical status can be reversed, promoting normal development with minimal or even absent sequelae. 1 The primary treatment objective with these conditions is to reestablish metabolic balance and, to achieve this, a range of strategies can be used either individually or in combination. Below, we will describe certain general principles of the treatment for this group of IEM and specific management for certain metabolic diseases.
General principles of treating IEM that present with manifestations of "intoxication"

Restricting substrate accumulation by means of diet
Since the 1950s, when it was discovered that phenylketonuria could be treated by restricting the quantity of phenylalanine in the diet, there have been great advances in treatment for other amino acid and organic acid metabolism diseases. In MSUD there are increases in the levels of leucine, isoleucine and valine in circulation and in homocystinuria there are increases in homocysteine and methionine.
Both are examples of aminoacidopathies in which the levels of toxic products can be restricted and controlled with specific diets. Nevertheless, for other pathologies, such as organic acidemias and certain urea cycle defects, although restricting protein intake can reduce the accumulation of toxic metabolites, neither the biochemical nor the clinical results are always favorable since there is accumulation of intermediate substrates which continue to be produced even after institution of the diet. 2 Additionally, it should be borne in mind that treatment must be continued for life, even after stabilization of symptoms. This has stimulated the development of foods designed for prolonged treatment of patients with metabolic diseases. The cost of these foods is elevated and their flavors, despite continuous improvements, remain different from a normal diet. 3 Classical galactosemia is caused by a deficiency of the galactose-1-phosphate uridyltransferase (GALT) enzyme and is already manifest in the neonatal period, triggered by galactose intake, generally from breastmilk, leading to cholestatic jaundice, liver failure, food intolerance, renal tubular dysfunction, sepsis and cataracts. The acute and hepatic forms can be rapidly reversed by the introduction of a diet free from lactose and galactose. However, studies have demonstrated that dietary restrictions do not avert the long term complications such as psychomotor development delays, verbal dyspraxia, motor abnormalities and hypogonadotropic hypogonadism, possibly as a result of endogenous galactose production, which is independent of restricted dietary intake. 4 Another example of application of a dietary strategy is supplementation with zinc for Wilson's disease because it aids with reducing the amount of copper absorbed by the intestine, competing for the same transport protein. 5 Table 1 lists some IEM that can benefit from dietary therapy and provides an indication of efficacy. up as a result of the fumarylacetoacetate deficiency ( Figure   1 ), the basic defect in this disease, averts hepatic complications such as cirrhosis and hepatocarcinoma. 7
Rapid removal of the toxic substrate
With urea cycle defects and organic acidemias and/or aminoacidopathies, branched chain amino acids are accumulated (leucine, isoleucine and valine) and very often it is not possible to wait for the levels of these toxic compounds to reduce in response to diet, making it necessary to force their removal in order to avoid/minimize related neurological damage. In order to achieve this, depending on the severity of the condition, the toxin can be removed directly (dialysis, for example) or medication can be administered to divert the metabolic pathway or to provoke rapid excretion in urine.
Although hemodialysis or hemofiltration continue to be the most rapid and effective methods for removing toxic metabolites, particularly ammonia, these procedures are technically challenging with neonates. In these cases peritoneal dialysis is the method of choice since it is more practical for use in a neonatal intensive care unit, but the risk of sepsis must always be borne in mind. 8 The use of sodium benzoate, phenylacetate or sodium phenylbutyrate with urea cycle defects promotes increased excretion of nitrogenated compounds, thereby reducing the accumulation of ammonia.
Although there are no rigorously conducted clinical trials that demonstrate the efficacy of L-carnitine, it has proven its efficacy for the treatment of certain organic acidemias and also of diseases that affect mitochondrial metabolism. The administration of L-carnitine has two main functions: the first is to promote formation of organic acylcarnitines that will reestablish the coenzyme A levels that are important for mitochondrial metabolism and are consumed heavily as a result of the accumulation of organic acids in circulation; the second is to bind to free organic acids so that they can be filtered and excreted effectively by the kidneys. 9 The effect of carnitine supplementation on diseases that affect its transport is dramatic, with recovery from the cardiomyopathy and prevention of further episodes of hypoketotic hypoglycemia. 6 Specifically with relation to the treatment of isovaleric aciduria, the use of high doses of glycine leads to the formation of isovalerylglycine, which is rapidly excreted by the kidneys, thereby reducing the high levels of toxic product.
Stimulation of residual enzyme activity
The catalytic properties of some enzymes are dependent on the participation of compounds that are not proteins, such as vitamins or minerals, which act as cofactors in many meta- tions of organic acidemia. 10 It is also known that approximately 50% of homocystinuria cases due to cystathionine β-synthase deficiencies respond to treatment with large quantities of pyridoxine (vitamin B6), which provokes increased enzyme activity and reduces serum homocysteine and, as a consequence, reduces ischemic events and ophthalmological damage related to the condition ( Table 2) . 11 Long-term use of vitamins (coenzymes) should be restricted to patients who have metabolic errors that are known to respond to treatment. It is also important to comment on the use of a vitamin cocktail for acutely ill patients, generally neonates, where there is a clinical suspicion of an IEM, but no diagnosis has yet been confirmed (Table 3 ). This measure is indicated for cases in which a long time will be needed for diagnostic workup, 
Organic acidemias
The term organic acidemia or aciduria refers to a group of disorders that are characterized by the excretion of organic acids in urine and are caused by enzyme deficiencies. Several Treatment over the long term:
1) Protein restriction with or without special formulae;
2) Supplementation with amino acids that are not part of the metabolic pathway, vitamins, mineral salts and carnitine;
3) Regular clinical follow-up with a specialized metabolic disorders team and a multidisciplinary team.
Urea cycle defects
The urea cycle is a series of six metabolic reactions that 
Treatment of lysosomal and peroxisomal diseases
Lysosomes and peroxisomes are cytoplasmatic organelles contained within their own membranes and with no DNA or ribosomes. They are present in all eukaryotic cells , and peroxisomes are especially abundant in the liver. 15, 16 They perform highly distinct functions in human metabolism.
Lysosomes are primarily involved in breaking down macromolecules, such as glycosaminoglycans and sphingolipids, while peroxisomes are primarily involved in the formation of plasmalogens (the most abundant class of myelin phospholipids) and in oxidative reactions associated with breaking down fatty acids (B or α-oxidation). 15, 16 The oxidation of fatty acids that takes place in peroxisomes exhibits certain differences in relation to the oxidation these substances undergo in the mitochondria: one of the main differences is that the peroxisomal system is more active in oxidation of very long-chain fatty acids (such as hexacosanoic acid) and
branched chain fatty acids (such as phytanic and pristanic acids), which derive from the fat of ruminant animals, meat and fish. 15, 16 The majority of lysosomal diseases are caused by the presence of pathogenic mutations to genes that code for enzymes that act within lysosomes (acidic hydrolases), whereas the majority of peroxisomal diseases are caused by mutations to genes that code for proteins involved in the transport of target substances (substrates of peroxisomal enzymes) into the interior of peroxisomes, or which code for proteins involved in directing peroxisomal proteins to the peroxisome (known as "peroxins") ( Table 4 ). Both peroxisomal proteins and lysosomal enzymes are synthesized in the rough endoplasmic reticulum and have markers (signal sequences) that allow them to be directed to the peroxisomes (in a process that is dependent on the "peroxins") or the lysosome (the signal sequence in this case consists of residues of mannose 6-phosphate acquired post-translation), respectively. Some lysosomal enzymes can be secreted and taken in by other cells, which is the phenomenon that provides the basis for one of the treatment strategies for this group of diseases: enzyme replacement therapy (ERT).
The clinical manifestations of lysosomal and peroxisomal diseases are, therefore, highly varied, although generally of a chronic and progressive character. It can be said that, in the case of lysosomal diseases, they are the result of a substrate that is present in higher quantities than normal (i.e., "accumulated " within lysosomes) ( Figure 3 ); in the case of the peroxisomal diseases, the clinical manifestations appear to result both from excess non-degraded substrates (see X-linked adrenoleukodystrophy, Table 4 ) and from missing products (see peroxisome biogenesis disorders, Table 4 ). Lysosomal diseases, therefore, are generally associated with morphological phenotypes classically known as "storage" or "accumulation", producing organomegalias and characteristic facies, and neurological phenotypes characterized by presence or absence of regression, whereas peroxisomal diseases can be associated with dysmorphias and malformations (the facial phenotype of Zellweger syndrome, for example, is said to be similar to that of Down Syndrome) and generally provoke neurological regression (Table 4) .
Treatment strategies
It is not the aim of this article to discuss each of the evidential bases for the specific therapies used to treat lysoso- The objective here is to describe, succinctly, the main treatment strategies available and to point out that using these innovative treatments will, in some cases, be associated with a certain degree of uncertainty with relation to their safety and efficacy. It is not uncommon for there to be an occasional lack of agreement between specialists, whether with relation to an indication itself or the to dose of medication that should be used. This is why it is recommended that individuals with lysosomal and peroxisomal diseases should be treated at tertiary care centers by professionals who are specialized in their management. Those who are interested in finding out about specific treatment in greater detail are invited to perform at their own literature reviews (one website which offers 
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a good level of up-to-date information on treatments for genetic diseases is GeneClinics 18 ).
We would also point out that there are many ongoing clinical trials investigating lysosomal and peroxisomal diseases (we suggest consulting www.clinicaltrials.gov 20 run by the United States National Institutes of Health).
Treatment of peroxisomal and lysosomal diseases
Treatment for the majority of peroxisomal diseases is essentially palliative, involving, in some cases, manipulating the patient's diet ( 
Conclusions
Few areas of medicine have advanced as much over recent years as treatments for IEM. Even though for many conditions the new treatments do not yet offer a cure, they 
Strategy Observations
Hematopoietic cell transplantation -Consider in all patients where diagnosis has been made early, especially those less than 12 months old, since this appears to be the only available therapy which offers the potential of interfering in the natural history of the brain disease.
-There is a basis in the literature for indicating its use in patients with the severe form of MPS I who are aged less than 18-24 months; infants with presymptomatic Krabbe disease; α-mannosidase deficiency; patients with late forms of Krabbe disease or metachromatic leukodystrophy. [21] [22] [23] ERT -Available for MPS I, MPS II, MPS VI, Gaucher disease, Fabry disease and Pompe disease. There is no consensus in the literature on the ideal age for starting ERT, nor on treatment indications for all patients.
Organ transplantation -Kidney, to treat chronic renal failure (Fabry disease, cystinosis). Treating IEM is a complex undertaking that should be carried out by a multidisciplinary team, of which a pediatrician is the key member, but which will also benefit from the presence of a geneticist, neuropediatrician, intensive care specialist and clinical pathologist in addition to other professionals such as a nutritionist, nurse and physiotherapist, to mention some examples.
The development of new treatment methods has made early diagnosis more important, stimulating neonatal screening programs, which in turn result in earlier, more successful, interventions. They also provide evidence that these diseases that are considered to be very rare are in fact little known and little diagnosed, which should change as the treatments that have been described briefly here become available.
